CANOMAD paraproteinaemic neuropathy
Evidence-based neurology checklist on canomad paraproteinaemic neuropathy: Epidemiology This usually affects men in their mid-50’s Clinical features Blood tests Magnetic resonance imaging (MRI) Nerve conduction studies (NCS) Nerve biopsy Differential diagnosis Treatment Acronym
Epidemiology
- This usually affects men in their mid-50’s
Clinical features
Blood tests
Magnetic resonance imaging (MRI)
Nerve conduction studies (NCS)
Nerve biopsy
Differential diagnosis
Treatment
Acronym
References
- Willison HJ, O'Leary CP, Veitch J, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001; 124:1968-1977.
- Krenn M, Keir G, Wieshmann UC. CANOMAD responding to weekly treatment with intravenous immunoglobulin (IVIg). BMJ Case Rep 2014 bcr-2013-202545.
- Hamedani AG, Bird SJ, Tamhankar MA. CANOMAD presenting as bilateral sixth nerve palsies. J Neuroophthalmol 2019; 39:397-398.
- Barnett MH, Barnett Y, Burke D, Willison H. Neurological picture. Spinal nerve root hypertrophy in chronic ataxic neuropathy with antiglycolipid IgM antibodies. JNNP 2011; 82:97.
- Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinaemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerve Syst 2006; 11:9-19.
- And 1 more. Subscribe to see the full list
